Adult's Still Disease
Conditions
Keywords
Tocilizumab Still
Brief summary
Patients with adult's Still disease suffer from acute inflammatory symptoms such as fever, arthritis, rash, and acute phase response often requiring high dose corticosteroids. In view of several case reports which have shown dramatic improvement in patients treated with Tocilizumab and a phase 2 study of this drug in children with Still's disease, the objective of the current study is to assess the efficacy and safety of Tocilizumab in patients with adult's Still disease.
Detailed description
This is a multicenter, open, study designed to investigate the effect of Tocilizumab, a monoclonal antibody to IL-6 receptor, on the management of active adult-onset Still's disease. Standard medication of corticosteroid will be given to all patients at the discretion of the treating physician. Visits will include : screening visit, week o, week 2 , and every 4 weeks after during 52 weeks After complying with the inclusion and exclusion criteria, patients will start treatment with Tocilizumab at a dosage of 8 mg/kg, every 2 weeks Patients will be assessed every visit for the presence of fever, tender and swollen joint, rash, dosage of corticosteroids and other DMARD's, CRP and ESR
Interventions
DRUGTocilizumab
Tocilizumab, IV, 8 mg/kg, every 2 weeks
Sponsors
Rambam Health Care Campus
Assaf-Harofeh Medical Center
Bnai Zion Medical Center
Tel-Aviv Sourasky Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Patients must have been diagnosed with adult-onset Still's disease according to the criteria of Yamaguchi (at least 5 criteria in total, including at least 2 major criteria), although these criteria do not have to be present at the time of inclusion in the study. Major criteria are:Fever ≥39°C for at least 1 week,Arthralgia lasting at least 2 weeks,Maculo-papular, non-pruritic skin rash,Leucocytosis .≥10,000/mm³) including ≥80% neutrophils;Minor criteria are:Pharyngitis or sore throat,Lymphadenopathy or splenomegaly,Liver enzyme (transaminase) abnormalities,Negative for rheumatoid factor or antinuclear antibodies * Patients aged \>18 * Capable of signing informed consent
Exclusion criteria
* active infections (especially sepsis and Epstein-Barr virus), * malignant disease (especially lymphomas), * other autoimmune or inflammatory disease (especially polyarteritis nodosa) * patients will be required to restrict other treatments for Still's disease to low-dose corticosteroids +/- non steroidal anti inflammatory drugs for at least the first 4 weeks of the study. * pregnant or breast-feeding women * women of childbearing potential unwilling to use adequate contraception and not become pregnant during the course of the study * previous treatment with other biologic antirheumatic agents will require a washout period before inclusion * history of listeriosis or latent or active tuberculosis * persistent chronic or active recurring infection requiring treatment with antibiotics, antivirals, or antifungals within 4 weeks prior to the screening visit, or history of frequent recurrent infections unacceptable per investigator judgment. * received administration of any live (attenuated) vaccine within 3 months prior to the inclusion visit * known history of Human Immunodeficiency Virus antibody; and/or positive Hepatitis B surface antigen , and/or positive Hepatitis C antibody at the screening visit. * history of recurrent herpes zoster. * history of prior articular or prosthetic joint infection * history of a hypersensitivity reaction, other than localised injection site reaction , to any biological molecule * uncontrolled diabetes * patients under dialysis * presence of any of the following laboratory abnormalities at the screening visit: haemoglobin \<8.5g/l, WBC \<3000/μL, platelet count \<150,000/μL, neutrophils \<1500/μL * AST or ALT \>2 Upper limit and bilirubin \>2 Upper limit
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| symptom-free or steroid-free remission at 52 weeks | 52 WEEKS |
Secondary
| Measure | Time frame |
|---|---|
| fever, ACR20, inflammatory markers (e.g. CRP, ferritin), need for rescue medication (e.g. methotrexate, anti-TNF alpha) , adverse events | 52 weeks |
Countries
Israel
Contacts
Primary ContactOri Elkayam, M.D
Backup ContactAyelet Brill, M.D
Outcome results
None listed